Asset
Renizgamglogene Autogedtemcel
Editas Medicine Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04853576 | phase1_2 | active_not_recruiting | 2021-05-04 | 2025-08-01 | Editas Medicine, Inc. | A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY) |
| NCT05444894 | phase1_2 | active_not_recruiting | 2022-04-29 | 2025-09-01 | Editas Medicine, Inc. | EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT) |
FDA applications (0)
This company has no applications containing this asset.